Edition:
United Kingdom

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

17.82USD
13 Dec 2017
Change (% chg)

$-0.09 (-0.50%)
Prev Close
$17.91
Open
$17.85
Day's High
$18.11
Day's Low
$17.60
Volume
146,856
Avg. Vol
169,852
52-wk High
$20.89
52-wk Low
$7.37

Chart for

About

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides... (more)

Overall

Beta: --
Market Cap(Mil.): $348.59
Shares Outstanding(Mil.): 29.57
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

04 Dec 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

04 Dec 2017

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

08 Nov 2017

BRIEF-Collegium receives FDA approval for sNDA for Xtampza® ER

* Collegium receives FDA approval for sNDA for Xtampza® ER Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER

* Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER

06 Nov 2017

BRIEF-Collegium reports Q2 loss per share $0.72

* Collegium reports second quarter financial results and provides corporate update

09 Aug 2017

Earnings vs. Estimates